Stemline Therapeutics

Stemline Therapeutics is a New York-based oncology company, founded in 2003 and now a subsidiary of the Italian Menarini Group. The company has achieved commercial success with its first-in-class therapy, ELZONRIS, for the rare and aggressive cancer BPDCN, and has expanded its portfolio with the acquisition of ORSERDU for ER+/HER2- metastatic breast cancer. Stemline operates as a fully integrated commercial entity within Menarini, leveraging its parent company's global infrastructure to develop and market targeted oncology therapies. Its strategy involves expanding the labels of its approved drugs into broader indications while advancing its pipeline.

Targeted therapy platform focused on CD123 (IL-3 receptor) using an engineered fusion protein (IL-3 ligand-diphtheria toxin payload), and oral selective estrogen receptor degraders (SERDs) for hormone-driven cancers.

In BPDCN, ELZONRIS faces no direct targeted therapy competition, but generic chemotherapy and stem cell transplant remain alternatives. In AML, it will compete with numerous approved targeted therapies, chemotherapy regimens, and emerging modalities. In breast cancer, ORSERDU competes with a wide array of endocrine therapies, CDK4/6 inhibitors, and other oral SERDs in development from larger pharmaceutical companies.